newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma to Participate in Three Upcoming Investor Conferences in October 2025

  • Ascentage Pharma Group International (NASDAQ: AAPG, HKEX: 6855) announced its management will participate in three investor conferences in October 2025.
  • The company will hold a fireside chat at the Piper Sandler Virtual Oncology Symposium on October 10 at 10:30 am EDT.
  • One-on-one & group investor meetings are scheduled for the J.P. Morgan Global Healthcare Shanghai Conference on October 16-17.
  • One-on-one investor meetings are planned for the 2025 BofA China Trailblazers Biotech Conference on October 20-21.
  • Ascentage Pharma is a commercial-stage integrated biopharmaceutical company focused on discovering, developing, & commercializing novel cancer therapies.
  • The company's first approved product, Olverembatinib, is a third-generation BCR-ABL1 inhibitor approved in China for chronic myelogenous leukemia (CML) patients with T315I mutations or resistance to prior TKIs.
  • Registrational Phase III trials for Olverembatinib include POLARIS-2 for CML, POLARIS-1 for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL), & POLARIS-3 for SDH-deficient GIST.
  • The second approved product, Lisaftoclax, is a Bcl-2 inhibitor approved in China for adult CLL/SLL patients previously treated with BTK inhibitors.
  • Four global Phase III trials for Lisaftoclax are ongoing: GLORA, GLORA-2, GLORA-3 for AML, & GLORA-4 for higher-risk MDS.
  • The company maintains partnerships with major pharmaceutical firms such as Takeda, AstraZeneca, Merck, Pfizer, & Innovent, & collaborates with institutions like Dana-Farber Cancer Institute & Mayo Clinic.
  • The press release includes forward-looking statements subject to risks & uncertainties detailed in the company's SEC filings, including its Form 20-F for the year ended December 31, 2024.